Trial · NCT03274076
Adverse events204
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 204
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypercholesterolemia | Investigations | Tofacitinib Double Blind 0-24 Weeks | 0 | 10 | 0 |
| other | Hypercholesterolemia | Investigations | Placebo Double Blind 0-24 Weeks | 0 | 5 | 0 |
| other | Hypercholesterolemia | Investigations | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | 1 | 10 | 1 |
| other | Hypercholesterolemia | Investigations | Placebo to Tofacitinib Open Label 24-48 Weeks | 0 | 4 | 0 |
| other | Hyperkalemia | Investigations | Tofacitinib Double Blind 0-24 Weeks | 0 | 10 | 0 |
| other | Hyperkalemia | Investigations | Placebo Double Blind 0-24 Weeks | 0 | 5 | 0 |
| other | Hyperkalemia | Investigations | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | 0 | 10 | 0 |
| other | Hyperkalemia | Investigations | Placebo to Tofacitinib Open Label 24-48 Weeks | 1 | 4 | 1 |
| other | Urinary Tract Infection | Renal and urinary disorders | Tofacitinib Double Blind 0-24 Weeks | 2 | 10 | 2 |
| other | Urinary Tract Infection | Renal and urinary disorders | Placebo Double Blind 0-24 Weeks | 0 | 5 | 0 |
| other | Urinary Tract Infection | Renal and urinary disorders | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | 0 | 10 | 0 |
| other | Urinary Tract Infection | Renal and urinary disorders | Placebo to Tofacitinib Open Label 24-48 Weeks | 0 | 4 | 0 |
| other | Hypertension | Cardiac disorders | Tofacitinib Double Blind 0-24 Weeks | 0 | 10 | 0 |
| other | Hypertension | Cardiac disorders | Placebo Double Blind 0-24 Weeks | 1 | 5 | 1 |
| other | Hypertension | Cardiac disorders | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | 1 | 10 | 1 |
| other | Hypertension | Cardiac disorders | Placebo to Tofacitinib Open Label 24-48 Weeks | 0 | 4 | 0 |
| other | Weight Gain | General disorders | Tofacitinib Double Blind 0-24 Weeks | 0 | 10 | 0 |
| other | Weight Gain | General disorders | Placebo Double Blind 0-24 Weeks | 1 | 5 | 1 |
| other | Weight Gain | General disorders | Tofacitinib to Tofacitinib Open Label 24-48 Weeks | 0 | 10 | 0 |
| other | Weight Gain | General disorders | Placebo to Tofacitinib Open Label 24-48 Weeks | 0 | 4 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03274076/events